Cancer patient management: Current use of next-generation sequencing in the EU TOP4.
J Cancer Policy
; 35: 100376, 2023 03.
Article
in English
| MEDLINE | ID: covidwho-2220948
ABSTRACT
BACKGROUND:
Next-generation sequencing (NGS) is recognised by a growing audience of medical professionals as a functional diagnostic tool in oncology. However, adoption in clinical routine proceeds haphazardly in Europe.METHODS:
A semi-structured interview survey was administered to 68 cancer care professionals in four EU countries between June-August and November-December 2021. Pre-screening questionnaires assessed sufficient NGS expertise, diverse geographical distribution, and professional roles.RESULTS:
Our findings provide a better understanding of current clinical, regulatory, and reimbursement practices for NGS in four EU countries.CONCLUSIONS:
Despite the impending European In-vitro Diagnostic Medical Devices Regulation (IVDR), tortuous national guidelines implementations and limping reimbursement policies are common traits across surveyed countries and produce disparity in access to advanced healthcare services amid regional distinctions. POLICYSUMMARY:
The evident information gap between involved parties and demand for consistent national guidelines could be filled by health economics analyses tailored to local specifics to provide factual leverage for a structured adoption of NGS testing.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Neoplasms
Type of study:
Guideline
/
Qualitative research
Limits:
Humans
Language:
English
Journal:
J Cancer Policy
Year:
2023
Document Type:
Article
Affiliation country:
J.jcpo.2022.100376
Similar
MEDLINE
...
LILACS
LIS